NASDAQ:ABMD
Delisted
ABIOMED Stock News
$381.02
+0 (+0%)
At Close: Mar 20, 2023
Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance
12:47pm, Monday, 19'th Sep 2022
Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.
3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio
09:47am, Friday, 02'nd Sep 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Abiomed's (ABMD) Impella Favored by Latest Study Result
02:18pm, Wednesday, 17'th Aug 2022
Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.
Why Shares of Abiomed Rose 18.4% in July
03:21pm, Monday, 08'th Aug 2022
The company's stock rose steadily throughout the month.
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2023 Results - Earnings Call Transcript
02:55pm, Thursday, 04'th Aug 2022
Abiomed, Inc. (NASDAQ:ABMD ) Q1 2023 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - President and Chief Executive Offic
Abiomed: Small Premium For Access To ~11% Normalized ROIC
01:45pm, Thursday, 04'th Aug 2022
Abiomed came in with another set of robust earnings yesterday, with double-digit growth from top to bottom. Earnings remain steady, however, the company exhibits the profitability features investors a
2 Medical Device Stocks With Extremely High GF Scores
11:07am, Monday, 18'th Jul 2022
The GF Score system from GuruFocus is a unique metric that takes into account a company's financial strength, profitability, growth, valuation and momentum to determine if the stock is likely to outpe
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
07:00am, Thursday, 14'th Jul 2022
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financials and host conference call to discuss the results for the first quarter of the fiscal year 2023 on August 4, 2022.
Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now
01:07pm, Friday, 17'th Jun 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
07:00am, Tuesday, 31'st May 2022
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present (live) at the William Blair 42nd Annual Growth Stock Conference.
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
12:02pm, Monday, 16'th May 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term
11:17am, Thursday, 12'th May 2022
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Abiomed, Inc. (ABMD) CEO Michael Minogue on Q4 2022 Results - Earnings Call Transcript
11:54am, Thursday, 28'th Apr 2022
Abiomed, Inc. (NASDAQ:ABMD ) Q4 2022 Results Conference Call April 28, 2022 8:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Michael Minogue - President and Chief Executive Of
Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates
10:32am, Thursday, 28'th Apr 2022
Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.
3 Medical Instruments Stocks to Buy Despite Industry Headwinds
10:32am, Tuesday, 19'th Apr 2022
The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most.
